Skip to main content

Table 4 Types of adverse events occurring in patients with spondylarthritis and rheumatoid arthritis treated with biologics

From: Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER

  Spondylarthritis Rheumatoid arthritis
Biologic and total exposure Infliximab 1,915 Etanercept 507 Adalimumab 5.7 Infliximab 5,521 Etanercept 1,724 Adalimumab 526
Type of adverse event Cases IR [95% CI] Cases IR [95% CI] Cases IR [95% CI] Cases IR [95% CI] Cases IR [95% CI] Cases IR [95% CI]
Infusion reaction 72 4.14 [3.29–5.22] 1 0.20 [0.03–1.4] 0 - 252 5.09 [4.50–5.76] 7 0.43 [0.21–0.91] 6 1.36 [0.61–3.03]
Infection 102 5.87 [4.83–7.13] 5 1.01 [0.42–2.43] 1 18.90 [2.66–134.14] 350 7.07 [6.37–7.85] 28 1.74 [1.20–2.52] 56 12.71 [9.78–16.52]
Cutaneous 22 1.27 [0.83–1.92] 2 0.40 [0.10–1.61] 1 18.90 [2.66–134.14] 50 1.01 [0.77–1.33] 21 1.30 [0.85–2.00] 40 9.08 [6.66–12.38]
Cytopenia 2 0.12 [0.03–0.46] 0 - 0 - 27 0.54 [0.37–0.80] 3 0.19 [0.06–0.58] 3 0.68 [0.22–2.11]
Neoplastic 6 0.35 [0.16–0.77] 1 0.20 [0.03–1.4] 0 - 20 0.40 [0.26–0.63] 8 0.50 [0.25–0.99] 1 0.23 [0.03–1.61]
Pulmonary 4 0.23 [0.09–0.61] 0 - 0 - 21 0.42 [0.28–0.65] 4 0.25 [0.09–0.66] 3 0.68 [0.22–2.11]
Cardiovascular 13 0.75 [0.43–1.29] 3 0.61 [0.20–1.88] 0 - 64 1.29 [1.01–1.65] 8 0.50 [0.25–0.99] 13 2.95 [1.71–5.08]
Endocrine 1 0.06 [0.01–0.41] 0 - 0 - 5 0.10 [0.04–0.24] 0 - 0 -
Gastrointestinal 25 1.44 [0.97–2.13] 3 0.61 [0.20–1.88] 0 - 32 0.64 [0.46–0.91] 5 0.31 [0.13–0.75] 19 4.31 [2.75–6.76]
Ophthalmologic 4 0.23 [0.09–0.61] 0 - 0 - 2 0.04 [0.01–0.16] 3 0.19 [0.06–0.58] 2 0.45 [0.11–1.82]
Psychiatric 3 0.17 [0.06–0.54] 0 - 0 - 2 0.04 [0.01–0.16] 0 - 6 1.36 [0.61–3.03]
Neurological 5 0.29 [0.12–0.69] 1 0.20 [0.03–1.43] 0 - 15 0.30 [0.18–0.50] 1 0.06 [0.01–0.44] 8 1.82 [0.91–3.63]
Gynecological 0 - 0 - 0 - 3 0.06 [0.02–0.19] 0 - 1 0.23 [0.03–1.61]
Urological 4 0.23 [0.09–0.61] 0 - 0 - 4 0.08 [0.03–0.22] 1 0.06 [0.01–0.44] 3 0.68 [0.22–2.11]
Others 17 Not estimated 2 Not estimated 0 Not estimated 83 Not estimated 10 Not estimated 23 Not estimated
  1. Data are presented as cases documented and as incidence rate (IR) and 95% confidence interval (CI) per 100 patient-years of exposure.